Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1988 1
1989 4
1991 4
1992 2
1993 1
1995 1
1996 3
1997 4
1998 3
1999 1
2000 3
2001 3
2002 2
2003 5
2004 1
2005 1
2006 2
2008 1
2011 1
2012 3
2013 6
2014 5
2015 6
2016 8
2017 4
2018 2
2019 2
2020 2
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

78 results
Results by year
Filters applied: . Clear all
Page 1
Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.
Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, McNamara J, Bluestone JA; AbATE Study Team. Herold KC, et al. Among authors: ehlers mr. Diabetes. 2013 Nov;62(11):3766-74. doi: 10.2337/db13-0345. Epub 2013 Jul 8. Diabetes. 2013. PMID: 23835333 Free PMC article. Clinical Trial.
Targeting memory T cells in type 1 diabetes.
Ehlers MR, Rigby MR. Ehlers MR, et al. Curr Diab Rep. 2015 Nov;15(11):84. doi: 10.1007/s11892-015-0659-5. Curr Diab Rep. 2015. PMID: 26370695 Review.
78 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page